克立硼罗能有效治病吗？

Introduction: Criborole, a boron-based phosphodiesterase 4 inhibitor (PDE-4), is a nonsteroidal topical monotherapy that inhibits the phosphodiesterase (PDE)-4 enzyme in the skin. Criborole alters the inflammation of atopic dermatitis by inhibiting the degradation of cAMP by PDE4, thereby leading to downstream modifications of nuclear factor-kB and T cell signaling pathways and alleviating the signs and symptoms of atopic dermatitis.

Can the generic version of Criborole also be effective in treating diseases

At present, only the original pharmaceutical company Pfizer has been approved for marketing in China, and no company has yet been approved to produce generic versions of Criborole ointment. Therefore, it is impossible to know the efficacy and price of the generic version of Criborole. Generic drugs need to be approved by relevant departments before they can be marketed. If a generic version of Criborole is launched on the market, it means that the drug ingredients, mechanism of action, efficacy and other aspects of the generic version of Criborole are basically the same as the original version of Criborole, and it can also effectively treat diseases.

In two studies involving a total of 1,522 patients with mild to moderate atopic dermatitis, significantly more patients treated with criborole had an investigator-assessed "clear" or "almost clear" outcome compared with treatment with an emollient ointment alone (32.8% vs. 25.4% in Study 1, and 31.4% vs. 18% in Study 2).

For every 8-14 patients treated with the therapeutic effect of crisaborole, one additional patient developed a response compared to using emollient ointment alone. Itching may be relieved after a few days with criborole or an emollient ointment, but more patients experience further relief after about a week of treatment with criborole.

What are the side effects of criborole

The most common side effect of criborole is pain at the application site, such as burning or stinging. Criborole may also cause hypersensitivity reactions at the application site or at a distance. These symptoms can be severe and include urticaria, itching, swelling and erythema. If signs and symptoms of a hypersensitivity reaction occur, criborole should be discontinued immediately and appropriate treatment initiated. Crisaborole should be contraindicated in patients with known hypersensitivity to crisaborole or any component of this preparation.